EyeGene

아이진 · 185490

Industrials Commercial Services · KOSDAQ

Small-cap

Market cap US$47.7M (₩65.8B)

Overview

EyeGene is a South Korean biotech venture that develops experimental vaccines and gene therapies, treatments that work by introducing genetic material into the body to fight disease.

Its pipeline targets hard-to-treat conditions including age-related macular degeneration, diabetic retinopathy, and rare inherited retinal diseases, as well as infectious-disease vaccines. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company is advancing two core technology platforms: messenger-RNA-based vaccines and AAV (adeno-associated virus) gene therapies, while also co-developing near-term commercial products such as a meningococcal vaccine and a recombinant botulinum toxin to help fund its research.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$2.6M

▲ +6.3% YoY

Operating profit · FY2025

−US$7.1M

Loss narrowed

Net income · FY2025

−US$13.8M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$2.3M(₩3.1B)	US$2.4M(₩3.4B)	US$2.6M(₩3.6B)
Operating profit	−US$19.6M(−₩27.1B)	−US$9.6M(−₩13.3B)	−US$7.1M(−₩9.9B)
Net income	−US$16.3M(−₩22.4B)	−US$9.3M(−₩12.9B)	−US$13.8M(−₩19.1B)

Revenue

FY2023US$2.3M
FY2024US$2.4M
FY2025US$2.6M

Operating profit

FY2023−US$19.6M
FY2024−US$9.6M
FY2025−US$7.1M

Net income

FY2023−US$16.3M
FY2024−US$9.3M
FY2025−US$13.8M

Key ratios (FY2025)

ROE

-35.2%

Debt/Eq

25.4%

Op. margin

-276.2%

Net margin

-534.9%

Rev. YoY

▲ +6.3%

Why it matters

The company is developing its next-generation coronavirus mRNA vaccine through a co-development consortium formed with five domestic and international partners.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?